MRK Dec 2025 60.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:50AM EDT. Market open.
Loading interactive chart…
- Simply Wall St.
Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
- Zacks
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
- Business Wire
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
RAHWAY, N.J., May 09, 2024--Merck Provides Update on Phase 3 KEYNOTE-B21 Trial
© 2024 Yahoo. All rights reserved.